ArticleMedicine2026
The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and cancer prevalence among US adults: A cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lipid metabolism is recognized as a key player in carcinogenesis, but the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and overall cancer prevalence remains unclear in the US population. This study aimed to investigate the association between NHHR and cancer prevalence based on self-reported lifetime cancer diagnoses in a nationally representative US population. We utilized data from the National Health and Nutrition Examination Survey from 2007 to 2016. The primary exposure was NHHR, and the primary outcome was self-reported lifetime cancer diagnosis. Associations were assessed using weighted multivariable logistic regression models, with NHHR modeled as both a continuous variable and tertiles. Model 1 was unadjusted; Model 2 adjusted for age, sex, race/ethnicity, education level, marital status, and family income-to-poverty ratio; and Model 3 further adjusted for total cholesterol, glycated hemoglobin, physical activity, and drinking status. The analysis included adults aged 18 years or older with available NHHR and cancer-related information. Exploratory cancer-specific analyses were performed for prostate, breast, colorectal, and lung cancers. Among 26,416 participants, 2451 (9.0%) reported a lifetime cancer diagnosis. The mean age of the participants was 49.48 ± 17.67 years, and the mean NHHR was 2.96 ± 1.48. In the fully adjusted model, each unit increase in NHHR corresponded to 7% higher odds of cancer prevalence (odds ratio: 1.07 [95% confidence interval: 1.01-1.13]). NHHR tertiles were defined as T1 (0.45-2.11), T2 (2.11-3.11), and T3 (3.11-15.03). Compared with participants in the lowest tertile, those in the highest tertile had 22% higher odds of cancer prevalence (odds ratio: 1.22 [95% confidence interval: 1.04-1.48], P = .035). Subgroup analyses suggested potential effect modification by sex. Elevated NHHR levels were positively associated with cancer prevalence in US adults, suggesting that NHHR may be a potential biomarker warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.